83
Participants
Start Date
July 18, 2023
Primary Completion Date
December 18, 2026
Study Completion Date
December 18, 2026
Tobemstomig
Participants will receive intravenous (IV) tobemstomig every 3 weeks (Q3W) until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Pembrolizumab
Participants will receive IV pembrolizumab Q3W until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Nab-Paclitaxel
Participants will receive IV nab-paclitaxel weekly for 3 weeks, followed by 1 week off, until disease progression or until up to 24 months after the first treatment, whichever is sooner.
Oncosalud Sac, Lima
National Taiwan Uni Hospital, Taipei
Medical Oncology Centre of Rosebank, Johannesburg
Komarom-Eszergom Varmegyei Szent Borbala Korhaz, Tatabánya
Memorial Sloan-Kettering Cancer Center, New York
Ospedale San Raffaele, Milan
Novant Health Forsyth Medical Center, Winston-Salem
Novant Health Presbyterain Medical Center, Charlotte
Hospital Quiron de Madrid, Pozuelo de Alarcón
Hospital Universitario Virgen de La Arrixaca, El Palmar
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH, Essen
Ospedale Provinciale Santa Maria Delle Croci, Ravenna
Avera Cancer Institute, Sioux Falls
Dres. Andreas Köhler und Roswitha Fuchs, Langen
Centro Médico Zambrano Hellion, Monterrey
Centro de Investigacion Clinica de Oaxaca, Oaxaca City
Universitätsklinikum Ulm Am Michelsberg, Ulm
Cancer Blood and Specialty Clinic, Los Alamitos
Sheba Medical Center, Ramat Gan
Hadassah University Hospital - Ein Kerem, Jerusaelm
Fundación CENIT para la Investigación en Neurociencias, Buenos Aires
Sunshine Hospital, St Albans
Instituto Peruano de Oncología y Radioterapia, Lima
Hospital Araujo Jorge, Goiânia
Hospital do Cancer de Pernambuco - HCP, Recife
Hospital de Cancer de Barretos, Barretos
Clinica de Pesquisa e Centro de Estudos em Oncologia Ginecologica e Mamaria Ltda, São Paulo
Fakultni Thomayerova nemocnice, Praha 4 - Krc
Health Pharma Professional Research, Mexico City
OncoMed, Mexico City
Centro Medico Monte Carmelo, Arequipa
Instituto Nacional de Enfermedades Neoplasicas, Lima
?wi?tokrzyskie Centrum Onkologii, Kielce
Szpital Uniwersytecki w Krakowie, Oddzia? Kliniczny Kliniki Onkologii, Krakow
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Gangnam Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Center, Seoul
Hoffmann-La Roche
INDUSTRY